New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
10:48 EDTSA, RAX, TCS, ARNA, FOSLOptions with decreasing implied volatility: ARNA RAX FOSL TCS SA
News For ARNA;RAX;FOSL;TCS;SA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
08:25 EDTRAXData centers,connectivity firms should be owned into results, says Pacific Crest
Subscribe for More Information
April 17, 2015
10:43 EDTFOSLOptions with increasing implied volatility: PNK FOSL ARCP LO
Subscribe for More Information
April 16, 2015
10:51 EDTFOSLOptions with increasing implied volatility
Options with increasing implied volatility: PNK ARRY FOSL NSAM WUBA ARCP CSCO
April 15, 2015
10:31 EDTFOSLOptions with increasing implied volatility:
Options with increasing implied volatility: CLDN PNK TLM FOSL ARCP CSCO
April 14, 2015
10:50 EDTFOSLOptions with increasing implied volatility
Subscribe for More Information
April 13, 2015
10:48 EDTFOSLOptions with increasing implied volatility
Options with increasing implied volatility: CLDN WETF EWH FOSL FXI TLM PRGO ATHN SYMC MAC
April 10, 2015
08:06 EDTARNAEisai and Arena Pharmaceuticals complete trials of formulation of lorcaserin
Subscribe for More Information
April 9, 2015
10:00 EDTRAXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:18 EDTTCSBofA/Merrill retail analysts hold an analyst/industry conference call
Subscribe for More Information
09:13 EDTRAXRackspace downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
April 8, 2015
16:24 EDTFOSLFossil files to sell 120,475 shares of common stock for holders
April 7, 2015
09:23 EDTARNAOn The Fly: Pre-market Movers
Subscribe for More Information
08:03 EDTARNAArena Pharmaceuticals receives additional patent for Belviq from USPTO
Arena Pharmaceuticals and Eisai announced that the US Patent and Trademark Office granted Arena US Patent No. 8,999,970, which describes a method for selecting appropriate patients based on renal function for BELVIQ, a serotonin 2C receptor agonist approved for weight management. In addition to this method-of-treatment patent, composition of matter patents for BELVIQ are issued in major jurisdictions globally that, in most cases, are capable of continuing into 2023. Arena has filed applications for patent term extension on patents directed to composition of matter in the United States, which, if granted, would extend the composition of matter patent term for BELVIQ into 2026 or potentially 2027.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use